| Ytd | -66.88% | |
| 1y | -89.23% |
| Open | 1.02 | Prev Close | 1.04 | Low | 1.04 | High | 1.04 | Mkt Cap | 4.06M |
| Vol | 377.00 | Avg Vol | 61.20K | EPS | -1.32 | P/E | N/A | Forward P/E | -0.13 |
| Beta | 0.15 | Short Ratio | 0.11 | Inst. Own | 8.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 1.05 | 200-d Avg | 2.69 | 1yr Est | 12.75 |
REVB News
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the
Revelation Biosciences, Inc. 4,272,500 Shares of Common Stock This prospectus relates to the resale,
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01292026_REVB_Sorensen.pdf
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announce
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP ex
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could suppor
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients.Gemi
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08082025_REVB_Sorensen.pdf
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(7.01) per share which missed the
https://endpoints.news/cder-director-tidmarsh-will-be-acting-head-of-fda-biologics-center-following-
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07092025_REVB_Sorensen.pdf
U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices we
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic